How to Value a Medspa (Medical Spa) in 2026

The medspa industry has gone from niche to mainstream in under a decade, and the M&A activity is following. Ideal Image, LaserAway, SkinSpirit (acquired by Allergan Aesthetics), AesthetiCare — the platform builders are actively consolidating this space. PE firms that cut their teeth rolling up dental practices and dermatology clinics have turned their attention to medspas, and for good reason: the economics are compelling.

I've valued medspas ranging from single-room Botox practices to multi-state chains with 20+ locations. The valuation dynamics are nuanced because medspas blend healthcare, retail, and services into a model that doesn't fit neatly into traditional valuation frameworks. Here is how it actually works.

The Cash-Pay Advantage

The single most important structural advantage of a medspa is that it operates almost entirely outside the insurance system. Botox, dermal fillers, laser treatments, CoolSculpting, chemical peels, IV therapy, PRP — none of this is covered by insurance. Your customers pay cash, credit card, or use a medical financing provider like CareCredit or Cherry.

Why does this matter for valuation? Because insurance-dependent practices (primary care, orthopedics, cardiology) face perpetual reimbursement risk. One payer contract change can wipe out 15% of revenue overnight. Medspas have zero insurance dependency, zero claim denials, zero AR aging problems, and zero payer mix risk. Buyers and their investors understand this and are willing to pay premium multiples for the stability of a cash-pay model.

The typical medspa collects payment at the time of service or via prepaid packages. Days sales outstanding is essentially zero. Compare that to a physician practice where DSO routinely runs 45-60 days and 5-10% of revenue never gets collected. That working capital efficiency translates directly into higher free cash flow and higher valuations.

Valuation Multiples: Single Location vs. Multi-Location

The valuation gap between a single medspa and a multi-location group is one of the widest I see in any industry:

• Single location, owner-operated: 3-5x SDE. A medspa doing $1.2M revenue with $300K SDE sells for $900K to $1.5M. Buyer is typically another practitioner or a first-time owner with an SBA loan.
• 2-4 locations with management: 5-7x EBITDA. The multiple expands because you've proven the model scales. EBITDA of $500K across three locations might yield $2.5M to $3.5M.
• 5+ locations or $3M+ EBITDA: 7-10x EBITDA. This is where PE platforms become your buyer pool. A five-location group generating $1.5M EBITDA attracts offers of $10.5M to $15M.
• Branded platforms (10+ locations): 10-14x EBITDA. At this scale, you're not selling a collection of medspas — you're selling a brand, a management system, and a growth engine.

Treatment Mix: Where the Margin Lives

Not all medspa revenue is created equal, and buyers will decompose your treatment mix to assess quality of earnings.

Injectables (Botox, Dysport, fillers) are the highest-margin services in most medspas. Gross margins on injectables run 60-70% when you account for product cost and injector compensation. More importantly, injectables generate recurring demand — Botox wears off every 3-4 months, fillers every 6-18 months. A patient who starts injectables in their 30s may continue for decades. This built-in repeat purchase cycle is why buyers overweight injectable revenue in their valuation models.

Laser and energy-based treatments (IPL, laser hair removal, skin resurfacing, body contouring) carry lower margins — typically 40-55% — because the equipment costs are high and the treatments require more time per session. However, laser services bring patients into the ecosystem who often become injectable patients over time. Buyers view laser revenue as both standalone revenue and a patient acquisition channel.

Body contouring (CoolSculpting, EMSculpt, truSculpt) is a mixed bag. The equipment is expensive ($100K-$300K per device), the treatment margins are lower (35-45%), and the repeat rate is moderate. A medspa that has invested heavily in body contouring devices with low utilization is a concern for buyers — they see expensive capital assets generating thin returns.

The ideal treatment mix for maximum valuation: 40-50% injectables, 25-30% laser treatments, 15-20% skin care and facials, and 10-15% body contouring. This mix delivers strong blended margins, high repeat rates, and diversification across treatment modalities.

Revenue Per Treatment Room: The Efficiency Metric

Sophisticated medspa buyers think about revenue per treatment room the way hotel investors think about RevPAR. A well-run medspa treatment room should generate $250K-$400K in annual revenue. If you have four treatment rooms doing $1.2M total, that's $300K per room — right in the sweet spot.

If your rooms are generating under $200K each, a buyer sees underutilization — you're paying rent on space that isn't producing. If you're above $400K per room, you're likely capacity-constrained, which is actually a positive signal for a buyer because it means there's pent-up demand and a clear path to revenue growth through expansion.

Injector Retention: The Risk That Keeps Buyers Up at Night

Here is the single biggest risk factor in medspa valuation: your injectors are your business. A skilled nurse injector or PA with a loyal patient following can walk out the door and take 30-50% of your injectable revenue with them. I have seen it happen, and it is devastating.

Buyers will scrutinize your injector relationships obsessively. What they want to see: employment agreements with enforceable non-competes (to the extent permitted by state law), compensation structures that incentivize retention (base plus production bonuses, not 1099 contractor arrangements), and tenure. An injector who has been with you for five years is a significantly lower flight risk than one who started six months ago.

The smartest medspa owners I've worked with build the brand around the practice, not the injector. "Glow Medical Spa" has a website, a social media presence, and a reputation that exists independently of any single provider. "Sarah's Injectable Artistry by Sarah Johnson, NP" has a key-person problem. Buyers pay 1-2x more SDE for the former than the latter.

Membership and Subscription Revenue

The trend toward membership models in medspas is one of the most valuation-accretive developments in the industry. A medspa membership might cost $99-$299 per month and include a monthly service (Botox touch-ups, a facial, a laser session) plus discounts on additional treatments.

Why do buyers love this? Because membership revenue is predictable, recurring, and has high retention (members typically stay 18-24 months). A medspa with 300 members paying $199/month has $717K in annualized recurring revenue — that's a revenue floor that exists regardless of walk-in traffic, marketing spend, or seasonal fluctuations.

Medspas with membership revenue exceeding 25% of total revenue consistently sell at 1-2x EBITDA premium over those with purely transactional models. If you don't have a membership program, implementing one 12-18 months before a sale is one of the highest-ROI moves you can make.

The Medical Director Question

Every medspa operates under the medical supervision of a licensed physician — the medical director. The structure of this relationship matters for compliance and for valuation.

Buyers want to see a medical director arrangement that is clean, compliant, and transferable. A medical director who is a passive supervisor being paid a reasonable monthly fee ($2,000-$5,000/month depending on scope) and who is not the owner is ideal. A medical director who is the owner, the primary practitioner, and the person every patient relationship depends on is a significant risk factor.

State regulations vary dramatically. In some states, non-physicians can own medspas outright. In others, only a physician can own a medical practice, which means the medspa must operate under a management services organization (MSO) structure. Buyers — especially national platforms — are deeply familiar with these regulatory nuances and will structure their acquisition accordingly, but surprises in this area kill deals.

Marketing Efficiency: Your Customer Acquisition Cost

Medspas are marketing-intensive businesses. Between Google Ads, Instagram, TikTok, influencer partnerships, and referral programs, marketing spend typically runs 10-20% of revenue. Buyers look closely at your customer acquisition cost (CAC) and your patient lifetime value (LTV).

A well-run medspa has a CAC of $100-$250 per new patient and a LTV of $2,000-$5,000+. That 10-20x LTV/CAC ratio is attractive. But if your CAC is $400+ and your average patient comes once and never returns, you have a leaky bucket that buyers will discount heavily.

Review data matters too. A medspa with 500+ Google reviews averaging 4.8 stars has built a marketing asset that generates organic patient flow independent of paid advertising. That organic engine has real value — buyers know they can reduce marketing spend without proportionally reducing patient volume.

The Bottom Line

Medspa valuations are rising because the industry fundamentals are strong: cash-pay model, high margins, recurring patient demand, and a massive addressable market driven by demographic trends and social media normalization of aesthetic treatments. The PE platforms are here, they are well-capitalized, and they are paying real multiples for quality operations.

The owners who capture the highest valuations are the ones who build beyond a single-provider practice: diversified treatment mix weighted toward injectables, membership revenue providing a recurring base, strong injector retention through smart compensation structures, and a brand that lives independently of any one person. Do that work, and you'll find no shortage of buyers willing to pay 7-10x for what you've built.